



The Role of Nitric Oxide in Enhancing Erythropoiesis in Sick Cell Disease

* Emmanuel Ifeanyi Obeagu

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.

Article Info:

Article History:

Received 09 May 2025

Reviewed 11 June 2025

Accepted 28 June 2025

Published 15 Sep 2025

Cite this article as:

Obeagu EI, The Role of Nitric Oxide in Enhancing Erythropoiesis in Sick Cell Disease, International Journal of Medical Sciences & Pharma Research, 2025; 11(3):8-12 DOI: <http://dx.doi.org/10.22270/ijmspr.v11i3.151>

*Address for Correspondence:

Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe

Abstract

Sickle cell disease (SCD) is a hereditary blood disorder characterized by the production of abnormal hemoglobin, leading to the sickling of red blood cells, vaso-occlusion, hemolysis, and chronic organ damage. One of the key challenges in SCD is impaired erythropoiesis, which results from the continuous destruction of sickled red blood cells and a compensatory increase in red blood cell production. Nitric oxide (NO), a critical endothelial signaling molecule, has been identified as a key regulator of erythropoiesis. NO influences the differentiation, proliferation, and survival of erythroid progenitor cells, thereby playing a vital role in maintaining healthy red blood cell production. In SCD, NO bioavailability is often reduced due to the hemolysis of red blood cells, which releases cell-free hemoglobin that scavenges NO. This depletion of NO further exacerbates the anemia and contributes to vascular dysfunction in SCD patients. Restoring NO availability may therefore be crucial for improving erythropoiesis and reducing the anemia that is characteristic of SCD. Research has shown that NO can enhance the expression of transcription factors involved in erythropoiesis and increase the production of fetal hemoglobin (HbF), which has a protective effect against sickling.

Keywords: Nitric oxide, erythropoiesis, sickle cell disease, hemoglobinopathies, vascular health

Introduction

Sickle cell disease (SCD) is a genetic hemoglobinopathy caused by a mutation in the β -globin gene, leading to the production of abnormal hemoglobin, HbS. Under low oxygen conditions, HbS polymerizes, causing red blood cells to assume a rigid, sickle-shaped form, which can block blood flow, leading to vaso-occlusion and a range of complications, including pain crises, organ damage, and chronic anemia. The continuous destruction of these sickled cells, known as hemolysis, results in a constant need for red blood cell replenishment. To compensate for the shortened lifespan of sickled red blood cells, the body attempts to increase erythropoiesis, the production of new red blood cells. However, this compensatory mechanism is often insufficient, leading to persistent anemia in SCD patients¹⁻³. Nitric oxide (NO) is a gaseous signaling molecule that plays a crucial role in many physiological processes, including vasodilation, blood flow regulation, and immune response modulation. NO is produced by endothelial nitric oxide synthase (eNOS) in the endothelium of blood vessels and is involved in maintaining vascular homeostasis and promoting healthy red blood cell function. In the context of erythropoiesis, NO has been shown to influence the survival, differentiation, and proliferation of erythroid progenitor cells in the bone marrow, thus contributing to optimal red blood cell production. The impact of NO

on erythropoiesis in SCD, however, remains an area of active research⁴⁻⁶.

In SCD, NO bioavailability is often compromised due to the effects of hemolysis. The release of cell-free hemoglobin into the bloodstream, a result of the constant destruction of sickled red blood cells, leads to the scavenging of NO. Cell-free hemoglobin binds to NO, rendering it inactive and diminishing its availability for endothelial and erythroid cells. The depletion of NO contributes to several pathological features in SCD, including vascular dysfunction, endothelial damage, and impaired erythropoiesis. Therefore, understanding how NO deficiency influences the erythropoiesis process in SCD is crucial to developing targeted therapies aimed at restoring NO bioavailability and improving red blood cell production in affected individuals⁷⁻⁸. One of the key challenges in SCD management is addressing the ineffective erythropoiesis and the associated anemia. Despite an increased production of erythroid progenitor cells in the bone marrow, these cells often fail to mature effectively due to the reduced availability of NO. NO is known to play a role in regulating the transcription factors responsible for erythropoiesis, including GATA-1 and NF- κ B, which are critical for the differentiation and survival of erythroid cells. NO's influence on hemoglobin production also plays a key role, as the production of fetal hemoglobin (HbF) can reduce the polymerization of HbS, leading to less sickling of red blood cells. This

has raised interest in exploring NO as a therapeutic target for enhancing erythropoiesis and improving the clinical outcomes of SCD patients⁹⁻¹¹.

Recent research has suggested that increasing NO availability could provide therapeutic benefits in SCD by improving erythropoiesis, increasing fetal hemoglobin production, and mitigating the vascular and hematological complications associated with the disease. Several approaches have been explored to restore NO bioavailability, including the use of NO donors, L-arginine supplementation (as the precursor for NO production), and phosphodiesterase inhibitors that promote the action of NO in the blood vessels. These strategies aim to alleviate vascular dysfunction, promote healthier red blood cells, and potentially reduce the severity of anemia in SCD patients¹²⁻¹³. In addition to these pharmacologic approaches, gene therapy holds promise as a more definitive treatment for restoring NO bioavailability and improving erythropoiesis in SCD. Advances in gene-editing technologies, such as CRISPR-Cas9, offer the potential to correct the underlying genetic mutation causing HbS or to induce the production of fetal hemoglobin, which does not sickle under low oxygen conditions. These innovations, combined with therapies targeting NO, could transform the management of SCD, reducing the frequency of vaso-occlusive crises and improving the overall quality of life for affected individuals¹⁴⁻¹.

Nitric Oxide and Erythropoiesis

Nitric oxide (NO) plays a critical role in regulating erythropoiesis, the process through which new red blood cells (RBCs) are produced. Erythropoiesis is tightly controlled by a network of signaling molecules, transcription factors, and environmental cues, including oxygen levels. Among these, NO has emerged as a key player in promoting the survival, proliferation, and differentiation of erythroid progenitor cells, the precursors to mature RBCs. NO modulates erythropoiesis by influencing several cellular processes, including erythroid progenitor cell self-renewal, differentiation into mature erythrocytes, and the induction of heme biosynthesis. Furthermore, NO interacts with erythropoietin (EPO), the hormone responsible for stimulating erythropoiesis, to enhance the responsiveness of erythroid progenitor cells to EPO stimulation¹⁶⁻¹⁷. One of the key ways NO influences erythropoiesis is by regulating the activity of transcription factors such as GATA-1, a major regulator of erythroid differentiation. NO has been shown to enhance GATA-1 expression in erythroid precursors, thus facilitating their maturation into fully functional RBCs. Additionally, NO promotes the survival of erythroid progenitor cells by modulating apoptotic pathways. In this context, NO prevents apoptosis of developing erythroid cells, thereby ensuring the maintenance of a sufficient pool of erythroblasts. The effect of NO on erythropoiesis also extends to the regulation of heme synthesis, a critical process for hemoglobin production. NO stimulates the enzyme heme oxygenase-1 (HO-1), which in turn regulates iron

metabolism and enhances the production of heme, the iron-containing component of hemoglobin¹⁸.

In the context of sickle cell disease (SCD), the role of NO in erythropoiesis becomes even more critical. In SCD, the premature destruction of sickled red blood cells leads to chronic anemia and compensatory hyperproduction of erythroid precursors. However, due to the reduced bioavailability of NO caused by hemolysis, erythropoiesis is often ineffective. The release of cell-free hemoglobin into the bloodstream scavenges NO, diminishing its ability to modulate erythropoiesis and endothelial function. This reduction in NO bioavailability impairs the maturation of erythroid progenitors and limits the ability of the bone marrow to compensate for the loss of RBCs. Moreover, the decreased NO levels exacerbate the vascular complications in SCD, contributing to endothelial dysfunction and an increased risk of vaso-occlusive crises¹⁹⁻²⁰. Restoring NO bioavailability in SCD could have significant therapeutic implications for enhancing erythropoiesis. By replenishing NO levels, it may be possible to improve the maturation and survival of erythroid progenitor cells, enhance heme biosynthesis, and increase the production of fetal hemoglobin (HbF). HbF, a type of hemoglobin that is not prone to sickling, is of particular interest in SCD treatment because its increased production can reduce the severity of the disease. Therefore, therapeutic strategies aimed at restoring NO levels, such as the use of NO donors, L-arginine supplementation, or gene therapy, could help improve erythropoiesis and alleviate some of the hematological complications of SCD²¹. In addition to its direct effects on erythropoiesis, NO's role in regulating oxygen delivery to tissues also has important implications for SCD. By promoting vasodilation and improving blood flow, NO can help reduce the risk of vaso-occlusion, a hallmark of SCD. This, in turn, could improve tissue oxygenation, providing a more favorable environment for erythroid progenitor cells in the bone marrow to differentiate and mature. Enhancing NO availability may also reduce the severity of hemolysis by improving RBC deformability, which could further support the maintenance of a stable RBC population in SCD patients²².

The Impact of NO on Hemoglobin Production

Nitric oxide (NO) has a significant influence on hemoglobin (Hb) production, primarily through its effects on erythropoiesis and the regulation of heme biosynthesis. Hemoglobin is the iron-containing protein in red blood cells responsible for oxygen transport, and its production is intricately controlled by multiple factors, including genetic regulators, oxygen levels, and signaling molecules like NO. One of the critical roles of NO in hemoglobin production is its ability to modulate the expression and activity of key enzymes involved in the heme biosynthesis pathway. Heme, the iron-containing prosthetic group of hemoglobin, is synthesized from porphyrin precursors in the mitochondria of developing erythroid cells. NO influences the activity of enzymes in this pathway, particularly heme oxygenase-1 (HO-1), which plays a

pivotal role in the degradation of heme and the regulation of iron metabolism²³⁻²⁴. NO enhances heme biosynthesis by stimulating HO-1 activity, which in turn helps regulate iron availability for hemoglobin synthesis. Iron is a crucial cofactor for the production of heme, and HO-1-mediated catabolism of heme generates bioavailable iron, thus facilitating the continued synthesis of hemoglobin in erythroid cells. Additionally, NO has been shown to upregulate the expression of erythropoietin (EPO), a hormone that stimulates the proliferation and differentiation of erythroid progenitor cells. By increasing EPO levels, NO indirectly supports the production of hemoglobin by promoting the expansion of erythroid precursors that can produce mature red blood cells. This process is critical in conditions such as anemia, where enhanced erythropoiesis is necessary to compensate for red blood cell loss²⁵⁻²⁶.

In sickle cell disease (SCD), the production of functional hemoglobin is disrupted due to the presence of sickle hemoglobin (HbS). In SCD, the abnormal polymerization of HbS under low oxygen conditions leads to red blood cell sickling, hemolysis, and reduced hemoglobin function. This results in chronic anemia and a compensatory increase in erythropoiesis. However, the continuous destruction of sickled red blood cells also leads to a depletion of NO in the circulation. The hemolysis of red blood cells releases cell-free hemoglobin into the plasma, which binds to and inactivates NO, reducing its bioavailability. This decrease in NO levels impairs the ability of erythroid progenitors to mature effectively, exacerbating anemia and reducing the production of functional hemoglobin²⁷⁻²⁸. The relationship between NO and fetal hemoglobin (HbF) production is of particular interest in SCD. HbF is a type of hemoglobin that does not undergo sickling, making it a promising therapeutic target for improving outcomes in SCD. Research has shown that NO can stimulate the production of HbF, potentially mitigating the effects of HbS in sickle cell disease. One mechanism by which NO enhances HbF production is through the activation of transcription factors such as GATA-1 and NF-E2, which are involved in the regulation of hemoglobin gene expression. NO may also promote the switching of hemoglobin production from adult hemoglobin (HbA) to HbF in erythroid progenitors, thus increasing the proportion of red blood cells that are less susceptible to sickling. This HbF induction is a crucial aspect of therapeutic strategies aimed at improving the clinical course of SCD²⁹.

Therapeutic Strategies to Restore NO Bioavailability

Restoring nitric oxide (NO) bioavailability in sickle cell disease (SCD) is critical to improving erythropoiesis, alleviating anemia, and addressing the vascular complications that contribute to the morbidity of the disease. In SCD, hemolysis of red blood cells releases cell-free hemoglobin, which scavenges NO, leading to its decreased bioavailability and resulting in endothelial dysfunction, reduced vasodilation, and impaired erythropoiesis. Several therapeutic strategies have been

explored to restore NO bioavailability and mitigate these detrimental effects. These strategies include the use of NO donors, L-arginine supplementation, phosphodiesterase type 5 inhibitors (PDE5i), and gene therapies, each targeting different aspects of NO metabolism and signaling pathways³⁰.

1. NO Donors and Nitrite Therapy:

One approach to restore NO bioavailability is the use of NO donors or nitrite therapy. These therapies deliver NO directly into the bloodstream, bypassing the need for endothelial cells to produce NO. NO donors, such as sodium nitroprusside, or organic nitrate compounds like isosorbide dinitrate, can provide an exogenous source of NO. Another promising strategy involves the use of sodium nitrite, which, when administered, can be reduced to NO under low-oxygen conditions, particularly in tissues with low oxygen tension, such as in the microcirculation. This selective NO delivery may help improve blood flow and oxygenation in sickle cell patients, thereby enhancing erythropoiesis and reducing vaso-occlusion³¹.

2. L-Arginine Supplementation:

L-arginine, the precursor amino acid for NO synthesis, plays a vital role in endothelial NO production. In SCD, chronic hemolysis leads to a depletion of plasma L-arginine, further reducing NO bioavailability. Supplementing with L-arginine has been explored as a therapeutic strategy to restore NO production by endothelial cells and improve vascular function. Studies have shown that L-arginine supplementation can improve endothelial function, reduce pulmonary hypertension, and improve vasodilation in SCD patients. Furthermore, L-arginine supplementation may also enhance erythropoiesis by providing a sustained substrate for NO production, supporting the maturation of erythroid progenitors and potentially increasing fetal hemoglobin (HbF) production, which is beneficial in SCD³².

3. Phosphodiesterase Type 5 Inhibitors (PDE5i):

PDE5 inhibitors, such as sildenafil and tadalafil, are well known for their ability to increase cyclic GMP (cGMP) levels and promote vasodilation. In SCD, the reduction in NO bioavailability impairs the cGMP pathway, leading to vasoconstriction and endothelial dysfunction. By inhibiting the breakdown of cGMP, PDE5 inhibitors can enhance the effects of endogenous NO, improve vascular function and reduce the risk of vaso-occlusive crises. Clinical trials investigating the use of PDE5 inhibitors in SCD have shown promising results, with improvements in pulmonary hypertension, exercise tolerance, and overall vascular health. This approach may not only help restore vascular function but also enhance the delivery of oxygen to tissues, indirectly supporting erythropoiesis³³⁻³⁴.

4. Gene Therapy:

Gene therapy holds significant promise for restoring NO bioavailability in sickle cell disease by directly addressing the underlying genetic defect or enhancing the production of NO and its downstream effects. One

potential avenue is the use of gene editing techniques, such as CRISPR-Cas9, to modify hematopoietic stem cells (HSCs) and increase the expression of endothelial nitric oxide synthase (eNOS) or enhance the production of fetal hemoglobin (HbF). Increasing HbF levels can reduce the sickling of red blood cells and improve the overall hematological status of SCD patients. Additionally, gene therapy that targets pathways involved in NO production or its downstream signaling could provide a durable solution to the problem of NO deficiency in SCD. For instance, genetic manipulation of eNOS expression could improve NO production in the endothelial cells, thus alleviating the vascular complications and supporting erythropoiesis³⁵⁻³⁶.

5. Antioxidants and Other Adjunct Therapies:

In addition to direct NO-enhancing strategies, the use of antioxidants has been considered as a means to restore NO bioavailability. In SCD, oxidative stress is a key contributor to the depletion of NO, as reactive oxygen species (ROS) can degrade NO and impair its signaling. Antioxidants such as vitamin C, vitamin E, and N-acetylcysteine (NAC) can scavenge ROS and prevent the oxidation of NO, thus preserving its availability and function. Combining antioxidant therapies with NO donors or L-arginine supplementation may enhance the overall therapeutic effect by reducing oxidative damage and promoting a more favorable environment for NO production and action³⁷.

Conclusion

Nitric oxide (NO) plays a pivotal role in maintaining vascular homeostasis, regulating erythropoiesis, and supporting overall cardiovascular health. In sickle cell disease (SCD), the depletion of NO bioavailability due to hemolysis-induced scavenging by cell-free hemoglobin significantly contributes to vascular dysfunction, exacerbates anemia, and impairs red blood cell production. The resulting endothelial dysfunction, reduced vasodilation, and inadequate oxygenation of tissues lead to various complications, including vaso-occlusive crises and organ damage. Restoring NO bioavailability through various therapeutic strategies holds promise in addressing these challenges and improving the clinical outcomes for SCD patients. Multiple approaches, including NO donors, L-arginine supplementation, phosphodiesterase type 5 inhibitors, gene therapy, and antioxidant treatments, have shown potential to restore NO levels and enhance vascular function in SCD. NO donors and nitrite therapy can directly increase circulating NO levels, while L-arginine supplementation provides the necessary substrate for NO synthesis. PDE5 inhibitors support NO signaling by preventing the breakdown of cyclic GMP, thereby improving vasodilation and reducing pulmonary hypertension. Gene therapy approaches offer the possibility of long-term solutions by targeting genetic pathways that govern NO production and fetal hemoglobin (HbF) expression. Additionally, antioxidant therapies may help mitigate oxidative stress and preserve NO bioavailability.

Conflict of Interest: Author declares no potential conflict of interest with respect to the contents, authorship, and/or publication of this article.

Source of Support: Nil

Funding: The authors declared that this study has received no financial support.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data supporting in this paper are available in the cited references.

Ethics approval: Not applicable.

References

1. Gupta A. Sickle Cell Anemia and Related Hemoglobinopathies. In Decision Making Through Problem Based Learning in Hematology: A Step-by-Step Approach in patients with Anemia 2024: 269-289. Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-8933-1_21
2. Hassan MS, Nasrin T, Mahalka A, Hoque M, Ali S. A perspective on the genesis, diagnostics, and management of sickle cell disease. Egyptian Journal of Medical Human Genetics. 2024; 25(1):150. <https://doi.org/10.1186/s43042-024-00623-1>
3. Rajput HS, Kumari M, Talele C, Sajan C, Saggu V, Hadia R. Comprehensive Overview Of Sickle Cell Disease: Global Impact, Management Strategies, And Future Directions. Journal of Advanced Zoology. 2024; 45(1). <https://doi.org/10.53555/jaz.v45i1.3390>
4. Obeagu EI. Role of Autophagy in Modulating Oxidative Stress in Sickle Cell Disease: A Narrative Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(8):38-46. <https://doi.org/10.23880/hij-16000247>
5. Obeagu EI. Redox Regulation of Hemoglobin in Sickle Cell Disease: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(8):13-9.
6. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. Int Res Med Health Sci. 2023 Sep 11;6:12-7.
7. Xiao R, Li L, Zhang Y, Fang L, Li R, Song D, Liang T, Su X. Reducing carbon and nitrogen loss by shortening the composting duration based on seed germination index (SCD@ GI): feasibilities and challenges. Science of The Total Environment. 2024:172883. <https://doi.org/10.1016/j.scitotenv.2024.172883> PMID:38697528
8. Lin W, Lv X, Wang Q, Li L, Zou G. Nitrogen concentration dependent optical defects transition in single crystal diamond through low pressure high temperature annealing. Vacuum. 2025:114329. <https://doi.org/10.1016/j.vacuum.2025.114329>
9. Wood KC, Granger DN. Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clinical & Experimental Pharmacology & Physiology. 2007 Sep 1;34(9). <https://doi.org/10.1111/j.1440-1681.2007.04639.x> PMID:17645642
10. Dijkmans T, Djokic MR, Van Geem KM, Marin GB. Comprehensive compositional analysis of sulfur and nitrogen containing compounds in shale oil using GC× GC-FID/SCD/NCD/TOF-MS. Fuel. 2015; 140:398-406. <https://doi.org/10.1016/j.fuel.2014.09.055>
11. Muehle M, Asmussen J, Becker MF, Schuelke T. Extending microwave plasma assisted CVD SCD growth to pressures of 400 Torr. Diamond and Related Materials. 2017; 79:150-163. <https://doi.org/10.1016/j.diamond.2017.09.013>
12. Obeagu EI, Obeagu GU. Immunization strategies for individuals with sickle cell anemia: A narrative review. Medicine. 2024; 103(38):e39756. <https://doi.org/10.1097/MD.00000000000039756> PMID:39312357 PMCID:PMC11419550

13. Obeagu EI. Strategies for reducing child mortality due to sickle cell disease in Uganda: a narrative review. *Annals of Medicine and Surgery*. 2024; 10:97.
14. Obeagu EI. Erythropoietin in sickle cell anaemia: a review. *International Journal of Research Studies in Medical and Health Sciences*. 2020;5(2):22-8. <https://doi.org/10.22259/ijrsmhs.0502004>
15. Obeagu EI, Obeagu GU. Malnutrition in sickle cell anemia: prevalence, impact, and interventions: a review. *Medicine*. 2024 May 17;103(20):e38164. <https://doi.org/10.1097/MD.00000000000038164> PMID:38758879 PMCID:PMC11098235
16. Quemada M, Delgado A, Mateos L, Villalobos FJ. Nitrogen fertilization I: The nitrogen balance. In *Principles of agronomy for sustainable agriculture 2024*: 377-401. Cham: Springer International Publishing. https://doi.org/10.1007/978-3-031-69150-8_26
17. Krug EC, Winstanley D. The need for comprehensive and consistent treatment of the nitrogen cycle in nitrogen cycling and mass balance studies: I. Terrestrial nitrogen cycle. *Science of the total environment*. 2002; 293(1-3):1-29. [https://doi.org/10.1016/S0048-9697\(01\)01133-0](https://doi.org/10.1016/S0048-9697(01)01133-0) PMID:12109464
18. Zhang CC, Zhou CZ, Burnap RL, Peng L. Carbon/nitrogen metabolic balance: lessons from cyanobacteria. *Trends in plant science*. 2018; 23(12):1116-1130. <https://doi.org/10.1016/j.tplants.2018.09.008> PMID:30292707
19. Enwonwu CO, Xu XX, Turner E. Nitrogen metabolism in sickle cell anemia: free amino acids in plasma and urine. *The American journal of the medical sciences*. 1990; 300(6):366-371. <https://doi.org/10.1097/00000441-199012000-00005> PMID:2264574
20. Borel MJ, Buchowski MS, Turner EA, Peeler BB, Goldstein RE, Flakoll PJ. Alterations in basal nutrient metabolism increase resting energy expenditure in sickle cell disease. *American Journal of Physiology-Endocrinology and Metabolism*. 1998; 274(2):E357-364. <https://doi.org/10.1152/ajpendo.1998.274.2.E357> PMID:9486169
21. Jackson AA. The use of stable isotopes to study nitrogen metabolism in homozygous sickle cell disease. In *Genetic factors in nutrition*. 1984: 297-315. Academic Press, New York. <https://doi.org/10.1016/B978-0-12-715950-8.50024-X> PMCID:PMC7131065
22. Schnog JJ, Jager EH, van der Dijs FP, Duits AJ, Moshage H, Muskiet FD, Muskiet FA. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. *Annals of Hematology*. 2004; 83:371-375. <https://doi.org/10.1007/s00277-004-0856-9> PMID:15054669
23. Darghouth D, Koehl B, Madalinski G, Heilner JF, Bovee P, Xu Y, Olivier MF, Bartolucci P, Benkerrou M, Pissard S, Colin Y. Pathophysiology of sickle cell disease is mirrored by the red blood cell metabolome. *Blood, The Journal of the American Society of Hematology*. 2011; 117(6):e57-66. <https://doi.org/10.1182/blood-2010-07-299636> PMID:21135259
24. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM, Gladwin MT. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. *Jama*. 2005; 294(1):81-90. <https://doi.org/10.1001/jama.294.1.81> PMID:15998894 PMCID:PMC2065861
25. Zhou Y, Yu X, Nicely A, Cunningham G, Challa C, McKinley K, Nickel R, Campbell A, Darbari D, Summar M, Majumdar S. Amino acid signature during sickle cell pain crisis shows significant alterations related to nitric oxide and energy metabolism. *Molecular genetics and metabolism*. 2022; 137(1-2):146-152. <https://doi.org/10.1016/j.ymgme.2022.08.004> PMID:36030599
26. D'Alessandro A, Nouraie SM, Zhang Y, Cendali F, Gamboni F, Reisz JA, Zhang X, Bartsch KW, Galbraith MD, Espinosa JM, Gordeuk VR. Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment. *Haematologica*. 2023; 108(12):3418. <https://doi.org/10.3324/haematol.2023.283288> PMID:37439373 PMCID:PMC10690926
27. Obeagu EI, Prajapati SK, Maurya SD. Maternal Anemia in the Context of Infectious Diseases during Pregnancy: A Review, *International Journal of Medical Sciences and Pharma Research*, 2025;11(1):8-13 <https://doi.org/10.22270/ijmspr.v11i1.134>
28. Obeagu EI, Chukwu PH. Inclusive Healthcare Approaches for HIV-Positive Sickle Cell Disease Patients: A Review. *Current Research in Biological Sciences*. 2025;1(1):01-8.
29. Obeagu EI, Obeagu GU. Managing gastrointestinal challenges: diarrhea in sickle cell anemia. *Medicine*. 2024; 103(18):e38075. <https://doi.org/10.1097/MD.00000000000038075> PMID:38701274 PMCID:PMC11062666
30. Obeagu EI, Obeagu GU. Living with sickle cell in Uganda: A comprehensive perspective on challenges, coping strategies, and health interventions. *Medicine*. 2024 Dec 20;103(51):e41062. <https://doi.org/10.1097/MD.00000000000041062> PMID:39705436 PMCID:PMC11666137
31. Obeagu EI, Adias TC, Obeagu GU. Advancing life: innovative approaches to enhance survival in sickle cell anemia patients. *Annals of Medicine and Surgery*. 2024; 86(10):6021-6036. <https://doi.org/10.1097/MS9.0000000000002534> PMID:39359845 PMCID:PMC11444627
32. Bell V, Varzakas T, Psaltopoulou T, Fernandes T. Sickle cell disease update: new treatments and challenging nutritional interventions. *Nutrients*. 2024; 16(2):258. <https://doi.org/10.3390/nu16020258> PMID:38257151 PMCID:PMC10820494
33. Khan SA, Damanhoury G, Ali A, Khan SA, Khan A, Bakillah A, Marouf S, Al Harbi G, Halawani SH, Makki A. Precipitating factors and targeted therapies in combating the perils of sickle cell disease---A special nutritional consideration. *Nutrition & metabolism*. 2016; 13:1-2. <https://doi.org/10.1186/s12986-016-0109-7> PMID:27508000 PMCID:PMC4977632
34. Patel S, Patel R, Mukkala SR, Akabari A. Emerging therapies and management approaches in sickle cell disease (SCD): A critical review. *Journal of Phytonanotechnology and Pharmaceutical Sciences*. 2023; 3(3):1-1. <https://doi.org/10.54085/jpps.2023.3.3.3>
35. Obeagu EI, Prajapati SK, Maurya SD, Anemia in Pregnancy: Exploring Non-Iron Deficiency Causes, *International Journal of Medical Sciences and Pharma Research*, 2025;11(1):1-7 <https://doi.org/10.22270/ijmspr.v11i1.130>
36. Boma PM, Kaponda AA, Panda J, Bonnechère B. Enhancing the management of pediatric sickle cell disease by integrating functional evaluation to mitigate the burden of vaso-occlusive crises. *Journal of Vascular Diseases*. 2024; 3(1):77-87. <https://doi.org/10.3390/jvd3010007>
37. Obeagu EI, Chukwu PH. Inclusive Healthcare Approaches for HIV-Positive Sickle Cell Disease Patients: A Review. *Current Research in Biological Sciences*. 2025;1(1):01-8.